Tvardi Therapeutics, Inc.
NASDAQTvardi Therapeutics heads into its May 14 earnings print with analysts turning more negative and short sellers trimming — a setup that tells two different stories about where the stock goes from here. The clearest recent signal came from the Street. Barclays downgraded TVRD to Underweight on April 20, cutting its target from $4 to $3 — below the current price of $3.14. The same…
Snapshot as of 6 May 2026
Tvardi Therapeutics heads into its May 14 earnings print with analysts turning more negative and short sellers trimming — a setup that tells two different stories about where the stock goes from here. The clearest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TVRD — free to start on ORTEX.
Sign up for free →Open TVRD on ORTEX